Telephone
1.858.836.5000
Address
9001 Spectrum Center Boulevard San Diego, CA 92123
Description
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 22.19 - 39.13
Trade Value (12mth)
US$10,018,174.00
1 week
0.19%
1 month
6.72%
YTD
45.69%
1 year
54.96%
All time high
40.79
EPS 3 yr Growth
112.60%
EBITDA Margin
34.20%
Operating Cashflow
$1,401m
Free Cash Flow Return
25.10%
ROIC
18.30%
Interest Coverage
26.60
Quick Ratio
1.70
Shares on Issue (Fully Dilluted)
1476m
HALO Sector
Healthcare
Next Company Report Date
31-Jul-25
Ex Dividend Date (est.)
06-Nov-24
Next Dividend Pay Date (est.)
12-Dec-24
Reporting Currency
USD
Short Sell (% of issue)
0.19
Date | Announcements |
---|---|
04 November 24 |
Form 4 - Change of Beneficial Ownership
×
Form 4 - Change of Beneficial Ownership |
04 November 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
28 October 24 |
Form 10-Q for the Quarter Ended September 30, 2024
×
Form 10-Q for the Quarter Ended September 30, 2024 |
28 October 24 |
Amendment to Notice of Annual Meeting/Proxy Form
×
Amendment to Notice of Annual Meeting/Proxy Form |
25 October 24 |
ResMed Announces Results for the First Quarter of FY2025
×
ResMed Announces Results for the First Quarter of FY2025 |
25 October 24 |
Dividend/Distribution - RMD
×
Dividend/Distribution - RMD |
17 October 24 |
Form 4 - Statement of Changes in Beneficial Ownership
×
Form 4 - Statement of Changes in Beneficial Ownership |
14 October 24 |
Form 144 - Notice of Proposed Sale of Securities
×
Form 144 - Notice of Proposed Sale of Securities |
10 October 24 |
Form 4 - Statement of Changes in Beneficial Ownership
×
Form 4 - Statement of Changes in Beneficial Ownership |
10 October 24 |
Form 4 - Statement of Changes in Beneficial Ownership
×
Form 4 - Statement of Changes in Beneficial Ownership |
09 October 24 |
Form 144 - Notice of Proposed Sale of Securities
×
Form 144 - Notice of Proposed Sale of Securities |
09 October 24 |
Form 144 - Notice of Proposed Sale of Securities
×
Form 144 - Notice of Proposed Sale of Securities |
04 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
04 October 24 |
Notice of Annual General Meeting Additional Materials
×
Notice of Annual General Meeting Additional Materials |
04 October 24 |
ResMed to Report First Quarter Fiscal 2025 Results
×
ResMed to Report First Quarter Fiscal 2025 Results |
03 October 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
04 September 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
19 August 24 |
Director Appointment/Resignation
×
Director Appointment/Resignation |
19 August 24 |
Update - Dividend/Distribution - RMD
×
Update - Dividend/Distribution - RMD |
12 August 24 |
ResMed Form 10-k Annual Report
×
ResMed Form 10-k Annual Report |
05 August 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
02 August 24 |
ResMed Announces Results for the Fourth Quarter of FY2024
×
ResMed Announces Results for the Fourth Quarter of FY2024 |
02 August 24 |
Dividend/Distribution - RMD
×
Dividend/Distribution - RMD |
04 July 24 |
ResMed to Report Fourth Quarter Fiscal 2024 Results
×
ResMed to Report Fourth Quarter Fiscal 2024 Results |
02 July 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.